NEWS
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Cellectar Biosciences (NASDAQ: CLRB) announced two presentations on iopofosine I 131 at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague.
The first presentation by Dr. Jorge Castillo will showcase a case study of complete central nervous system clearance in a patient with Bing-Neel Syndrome (BNS), a rare complication of Waldenstrom's Macroglobulinemia (WM).
The second presentation by Dr. Andrei Shustov will review topline data from the CLOVER WaM pivotal study, the largest WM study to date in a highly refractory patient population.
Iopofosine I 131, Cellectar's lead product candidate, is a potential first-in-class cancer targeting agent that has demonstrated the ability to cross the blood-brain barrier and shown clinical activity in multiple hematologic malignancies involving the central nervous system.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1668Followers
93Following
13KVisitors
Follow